News

FDA Approves Higher Cosentyx Dose for Active AS

The U.S. Food and Drug Administration (FDA) has approved a label update to Novartis’ Cosentyx (secukinumab), doubling the previously recommended dose to 300 mg for adults with active ankylosing spondylitis (AS). “This approval gives clinicians added flexibility to ensure patients are able to achieve the best…

Video: Bionews’ Social Media Campaign Highlights #WhatMakesMeRare

In recognition of Rare Disease Day Feb. 29, Bionews Services launched a social media campaign last month asking patients to describe what makes them rare. Running Feb. 7–29, the #WhatMakesMeRare campaign was aimed at uplifting people with rare diseases by encouraging them to share their stories and perspectives. The…

Patients, Supporters Worldwide Recognizing Rare Disease Day 2020

An abundance of events are afoot around the world to mark Rare Disease Day 2020 on Feb. 29. The activities are focused on heightening awareness about rare diseases and the hundreds of millions of individuals they are thought to affect. Patients, caregivers, and advocates worldwide will sport denim ribbons…

New Variant in RELN Gene Linked to AS in Iranian Family

A new genetic variant in the RELN gene was identified in ankylosing spondylitis (AS) patients in the same family, an Iranian study reports. The study, “Identification of RELN varient p.(Ser2486Gly) in an Iranian family with ankylosing spondylitis: the first association of RELN and AS,” was published in the…